信迪利单抗联合XELOX方案治疗晚期胃癌的疗效及对血清肿瘤标志物的影响  

Efficacy of Cindilizumab Plus XELOX Regimen in Advanced Gastric Cancer And Its Effect on Serum Tumor Markers

作　　者：李莹莹 王娟娟 唐小慧 Li Yingying;Wang Juanjuan;Tang Xiaohui(Department of Oncology,Qidong Hospital,Nantong University,Nantong Jiangsu 226200,China)

机构地区：[1]南通大学附属启东医院肿瘤科,江苏南通226200

出　　处：《生命科学仪器》2024年第5期61-63,共3页Life Science Instruments

摘　　要：目的 探讨晚期胃癌患者联合采用信迪利单抗与XELOX方案的疗效及对患者血清肿瘤标志物的影响。方法 选择2021年1月至2024年3月期间南通大学附属启东医院收治的晚期胃癌患者68例,以随机方式分组。对照组34例予XELOX方案治疗,观察组34例在对照组基础上加用信迪利单抗治疗,比较治疗效果。结果 两组客观缓解率、疾病控制率对比,观察组较对照组更高,P<0.05。治疗前,两组血肿瘤标志物与免疫功能指标水平对比,P>0.05;治疗后,观察组肿瘤标志物与免疫功能水平均分别较对照组的优,P<0.05。两组不良反应率对比,P>0.05。结论 信迪利单抗联合XELOX治疗晚期胃癌的疗效可靠,可降低血清肿瘤标记物水平,并调节患者免疫功能,且不良反应可控。Objective:To investigate the curative effect of cindilizumab combined with XELOX regimen in patients with advanced gastric cancer and its influence on serum tumor markers.Methods:68 patients with advanced gastric cancer admitted to Qidong Hospital affiliated to Nantong University from January 2021 to March 2024 were randomly divided into control group and observation group,with 34 patients in each group.34 cases in the control group were treated with XELOX regimen,and 34 cases in the observation group were treated with sindilizumab on top of the control group..The curative effect、serum tumor markers、immune indexes and adverse reactions were compared between the two groups.Results:Comparing the objective remission rate and disease control rate of the two groups,the observation group was significantly higher than the control group,P<0.05.Before treatment,the levels of blood tumor markers and immune function indexes in the two groups were compared,P>0.05;After treatment,tumour markers in the observation group and the level of immune function index was better than that in the control group,P<0.05.The incidence of adverse reactions between the two groups was compared,P>0.05.Conclusion:Cindilizumab combined with XELOX can achieve good curative effect in the treatment of advanced gastric cancer,and can reduce the level of tumor markers and regulate the immune function of patients,and the adverse reactions can be controlled.

关 键 词：信迪利单抗 XELOX方案 晚期胃癌 血清肿瘤标志物 免疫功能 不良反应 

分 类 号：R735.2[医药卫生—肿瘤]